RIPK pathway, as a potential target, for cancer treatment - a review

Abstract

Cancer is one of the most feared diseases whose prevalence has been drastically increasing in recent years. Among different types of treatment options, the development of kinase-targeted cancer therapies is currently the most studied target for potential anti-cancer therapies. After G-protein-coupled receptors, protein kinases significantly grab the attraction as a target of developing anti-cancer drugs. Based on current research, this review article outlines receptor-interacting protein kinases specially RIP1 and RIP3 as attractive targets over other kinases in the treatment of numerous types of cancer, especially for their tumorigenesis functions in cancer metastasis.